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Abstract
Congenital hyperinsulinism (CHI) is a significant cause of hypoglycaemia in neonates and
infants with the potential for permanent neurologic injury. Accurate calculations of the inci-
dence of rare diseases such as CHI are important as they inform health care planning and
can aid interpretation of genetic testing results when assessing the frequency of variants in
large-scale, unselected sequencing databases. Whilst minimal incidence rates have been
calculated for four European countries, the incidence of CHI in the UK is not known. In this
study we have used referral rates to a central laboratory for genetic testing and annual birth
rates from census data to calculate the minimal incidence of CHI within the UK from 2007 to
2016. CHI was diagnosed in 278 individuals based on inappropriately detectable insulin
and/or C-peptide measurements at the time of hypoglycaemia which persisted beyond 6
months of age. From these data, we have calculated a minimum incidence of 1 in 28,389
live births for CHI in the UK. This is comparable to estimates from other outbred populations
and provides an accurate estimate that will aid both health care provision and interpretation
of genetic results, which will help advance our understanding of CHI.
Introduction
Congenital hyperinsulinism (CHI), a disorder of heterogeneous aetiology characterised by
dysregulated and inappropriate insulin secretion, is a significant cause of hypoglycaemia in
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Data Availability Statement: The genotype data
could be used to identify individuals and so cannot
neonates and infants with the potential for permanent neurologic injury. CHI can be tran-
sient or persistent. Transient CHI is usually associated with stress in the antenatal or perina-
tal period, such as intrauterine growth restriction or birth asphyxia, and typically resolves in
the first few months of life, the majority by 6 months of age [1, 2, 3]. Individuals with persis-
tent CHI continue to require medical therapy or surgery to stabilise blood glucose levels
and up to 50–65% of patients in this group are without an identified mutation in any of the
known CHI genes [4, 5]. Previous estimates of the incidence of CHI in outbred populations
have ranged from 1 in 27,000 in Ireland to 1 in 50,000 in the Netherlands [6, 7]. The precise
criteria for defining CHI however has varied between studies, at times have been unclear
and has often not distinguished between transient and persistent forms [8, 9, 5]. Moreover,
the incidence of CHI within the UK has yet to be determined. As accurate estimates are
needed for both health care provision and research purposes, we have now calculated the
minimal incidence of CHI within the UK based on referral rates to a central diagnostic
genetic testing laboratory.
Materials and methods
This study was approved by the North Wales Research Ethics Committee (517/WA/0327).
Consent was not obtained as the data were analysed anonymously. The incidence of CHI for a
region can be calculated from referral rates to a diagnostic laboratory and the annual birth
rate. As not all cases will necessarily be referred for testing, this will reflect a minimum inci-
dence for the region. The Exeter Molecular Genetics Laboratory, at the Royal Devon and Exe-
ter Hospital (Exeter, UK) is the sole centre for clinical genetic testing for CHI in the UK. As
the clinical care for patients with CHI in the UK is largely provided through two nationally
commissioned, National Health Service-funded centres, the referral rate for genetic testing for
this condition is high.
To calculate the minimal incidence of CHI over a 10-year period we identified all referrals for
genetic testing for CHI from England, Wales, Scotland and Northern Ireland from 2007 to 2016.
CHI was defined as having an inappropriate insulin and C-peptide measurement during hypo-
glycaemia in the clinical context of recurrent hypoglycaemia and high glucose infusion rate sug-
gestive of hyperinsulinism [10, 11] diagnosed within the first 12 months of life. Although both
insulin and C-peptide were measured, insulin was used as the primary biomarker with C-peptide
as a supporting adjunct. All cases had laboratory glucose levels<3 mmol/L with a concurrent,
unequivocally raised insulin level. Inclusion criteria were persistence of CHI beyond 6 months
or requirement for pancreatectomy to manage hypoglycaemia. Persistence of CHI was defined
as continuing need for medical therapy and/or dietary carbohydrate supplementation to prevent
hypoglycaemia. The cut-off of 6 months was used to exclude cases of transient CHI, associated
with environmental factors around the perinatal period, as most transient cases resolve within 6
months [1, 2, 3]. Data on the duration and management of CHI, including requirement for sur-
gery, was obtained from the genetic testing request form. If this information was not provided at
the time of testing, the referring physician was contacted to provide these details. Data on live
births from 2007 to 2016 was obtained from the Office of National Statistics (https://www.ons.
gov.uk/peoplepopulationandcommunity, accessed 27/07/19), National Records of Scotland
(https://www.nrscotland.gov.uk/statistics-and-data/statistics, accessed 27/07/19) and the
Northern Ireland Statistics and Research Agency (https://www.nisra.gov.uk/publications/birth-
statistics, accessed 24/08/19). There were a total of 7,892,004 live births in the United Kingdom
from 2007 to 2016 inclusive: 7,069,592 in England and Wales; 574,601 in Scotland and 247,811
in Northern Ireland. 95% Confidence intervals were calculated for the study population and the
estimates from other countries where data were available for calculation (S1 Table).
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Results
Between 2007 to 2016, 278 UK patients (55% male) referred for genetic testing had biochemi-
cally-confirmed CHI persisting for more than 6 months or had undergone pancreatic surgery
for CHI (74/278, 27%) (Fig 1). Median glucose was 1.8 mmol/L (interquartile range (IQR) 1.3,
2.3) with insulin 90 pmol/L (median; IQR 44,168) and C-peptide 700 pmol/L (median; IQR
374, 1224). CHI persisted beyond 12 months in 229 of these cases (82%). Consanguinity was
reported in 24/278 patients (8.6%). Disease-causing variants in known CHI genes were identi-
fied in 154 (55%) individuals, of which mutations in the potassium ATP channel genes ABCC8
and KCNJ11 were the most common (115/154, 74%). The pick-up rate for disease-causing var-
iants in patients with reported consanguinity was 16/24 (67%). The mutation detection rate in
the cohort is similar to previous reports [2, 5, 4]. Using these data and dividing by the number
of live births from 2007 to 2016 for England, Scotland, Wales and Northern Ireland, which was
7,892,004, the minimum annual incidence of CHI in the UK was calculated as 1 in 28,389 live
births (95% CI 1:25 000, 1:32 258) (Fig 2). This decreases to 1 in 34,463 for those with CHI at
12 months of age or older. Where a disease-causing variant was identified, the incidence was 1
in 51,247 for those with CHI at 6 months of age and 1 in 54,806 for those with CHI at 12
months.
Discussion
We have calculated an incidence of 1 case of CHI per 28,389 live births in the UK from 2007 to
2016. This estimate is similar to that previously reported for Ireland (1 in 27,000) but higher
than estimates for other outbred populations (Fig 2) [6, 7, 8, 9, 5]. Although this could reflect a
true increase in incidence, given the overlapping or near-overlapping 95% CI compared to
estimates from other countries, the difference is more likely due to the small sample sizes in
other studies (S1 Table). Regardless, this study provides an accurate estimate on the minimal
incidence of CHI in the UK, which was previously unknown.
A greater incidence of CHI could be due to a number of factors. Improved awareness of
CHI and a better understanding of the genetic aetiologies over the last decades is likely to have
resulted in an increase in detection and reporting of CHI cases. We did not detect an overall
trend of increasing incidence from 2007–2016 (S2 Table), however the increase in numbers
may well have occurred prior to this time period. Differences in inclusion criteria may have
also contributed with some studies using higher insulin thresholds, possibly due to differences
in assay sensitivity, and this could have resulted in underdetection of CHI [9].
Furthermore, although most cases of transient CHI resolve by 6 months of age, our cohort
may have included transient cases that had not yet resolved. However, given that 83% of cases
continued to persist at 12 months of age (Fig 1), this is unlikely to have played a significant
role. In our cohort, consanguinity was reported in 24 individuals; the pick-up rate for muta-
tions within this group was high (16/24, 67%) in keeping with the autosomal recessive nature
of the most common genetic aetiologies. This high prevalence of recessive genetic disease in
CHI can explain the much higher incidence rates of CHI in consanguineous populations: 1 in
2,675 in Saudi Arabia and 1 in 19,960 in Kuwait [12, 13].
The major limitation of this study is that it is derived from a single centre to which referrals
for genetic testing were voluntary. However, as CHI in the UK is managed by a highly-special-
ised service funded on a national level, most cases of CHI in which genetic testing would have
been clinically indicated (i.e. severity, persistence of disease or features suggesting a genetic
aetiology) would have been referred to the Exeter laboratory for testing. Moreover, as genetic
testing is government-funded it is unlikely that patients would have been tested outside of the
UK.
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The criteria for CHI diagnosis was a non-suppressed insulin and/or C-peptide level at the
time of hypoglycaemia. While the measurement of C-peptide may not be specific to the diag-
nosis of CHI, its use as an adjunct with serum insulin in the context of robust supportive clini-
cal criteria is reasonably justified and is unlikely to over-represent the reported incidence of
CHI. A further limitation of our study is that we were unable to determine persistence of CHI
in 104 patients. Given that these patients were lost to follow-up, it seems most likely that the
CHI was transient and would therefore be unlikely to affect the calculated incidence of persis-
tent CHI. Our calculation thus reflects the minimal incidence of CHI in the UK. It is important
to note that transient cases can be severe despite the self-resolving nature and have been
reported to be more common than persistent forms, consistent with the association with
Fig 1. Flow diagram showing the outcomes of referrals for genetic testing for congenital hyperinsulinism.
https://doi.org/10.1371/journal.pone.0228417.g001
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perinatal stress [9]. Transient CHI therefore deserves further study to establish its incidence
and natural history.
Ensuring accurate calculations of the incidence of disease has important implications for
both health care and medical research. The clinical management of CHI, particularly persistent
forms, can be complex, requiring input from endocrinology, specialised nuclear medicine
imaging, surgical expertise, allied health professionals and clinical laboratories [11]. Accurate
incidence data are therefore important for health services planning. As well, hypoglycaemia
can be due to causes other than CHI, and it is important to understand the incidence of CHI
relative to other aetiologies. Furthermore, as genetic sequencing technologies have become
more widely used both as clinical and research tools, rare genetic variants are increasingly
Fig 2. The incidence of congenital hyperinsulinism in the UK compared to other outbred populations. In the current study, CHI was diagnosed based on a non-
suppressed insulin and C-peptide level at the time of hypoglycaemia with persistence beyond 6 months of age or need for pancreatectomy. Incidence is expressed as the
number per 100,000 live births with the 95% confidence intervals (CI) provided with each estimate where calculated. The 95% CI could not be calculated for Ireland or
Japan as the estimates were based on unpublished or unavailable data, respectively.
https://doi.org/10.1371/journal.pone.0228417.g002
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identified which are often difficult to classify. One widely used approach to help determine
likely pathogenicity is to assess how frequently the variant appears in large population data-
bases such as the Genome Aggregation Database (gnomAD) [14, 15]. The success of this
approach however relies on accurate calculations of the incidence disease within the
population.
In conclusion we have shown that the incidence of CHI in the UK is at least 1 in 28,389 live
births. Current incidence estimates are imperative for both health care planning and accurate
interpretation of the results of genetic testing, which will help advance our understanding of
CHI.
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